Ceribell demonstrated strong revenue growth and notable expansion in accounts, particularly within the VA system. However, increased operating expenses and net loss were significant concerns. The company is actively managing tariff impacts with supply chain adjustments.
Company Guidance
In the recent earnings call, Ceribell provided updated guidance reflecting strong performance in the third quarter of 2025, with a total revenue of $22.6 million, marking a 31% increase from the same period in the previous year. The company announced a raised full-year revenue guidance to a range of $87 million to $89 million, representing a 34% year-over-year growth at the midpoint. Key drivers of this growth include an increase in active accounts, which reached 615 by the end of September, with an addition of 31 accounts over the prior quarter, and significant increases in utilization per account. Ceribell's focus on expanding patient access, advancing its product pipeline, and establishing point-of-care EEG as a standard in acute care is expected to unlock a $2 billion market opportunity, with potential expansion into pediatric and neonatal markets projected to add approximately $400 million. The company also highlighted the success of its SAFER-EEG clinical trial, which showed that their system reduces median time to EEG by 19 hours and severe disability rates by 18%, while also reducing ICU length of stay by 4.1 days. Looking ahead, Ceribell plans to continue leveraging its commercial strategy to drive further growth and penetrate deeper into existing accounts, with ongoing efforts to expand into neonatal and pediatric populations and develop new algorithms for conditions such as delirium and stroke.
Strong Revenue Growth
Total revenue for Q3 2025 was $22.6 million, reflecting a 31% increase over the same period last year.
Record Account Growth
Ceribell added 31 new accounts this quarter, marking the largest sequential increase since becoming a public company.
Expansion in VA System
Received FedRAMP High Authorization and successful pilot results leading to expanded use in VA hospitals.
Improved Gross Margin
Gross margin for Q3 2025 was 88%, up from 87% in the prior year period.
Subscription Revenue Growth
Subscription revenue increased by 44% from Q3 2024, indicating a strong recurring revenue base.
Ceribell, Inc. (CBLL) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CBLL Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$10.92
$11.78
+7.88%
Aug 05, 2025
$15.08
$12.78
-15.25%
May 08, 2025
$17.10
$15.97
-6.61%
Feb 25, 2025
$25.54
$25.20
-1.33%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ceribell, Inc. (CBLL) report earnings?
Ceribell, Inc. (CBLL) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).
What is Ceribell, Inc. (CBLL) earnings time?
Ceribell, Inc. (CBLL) earnings time is at Mar 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.